Skip to main content

Advertisement

Log in

Protein-losing enteropathy and gastropathy

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

  • The diagnosis of protein-losing enteropathy (PLE) should be considered in all patients with hypoalbuminemia and edema without other known causes, and established by plasma alpha1-antitrypsin (a1-AT) clearance or nuclear studies.

  • The therapy for PLE should focus principally on the treatment of the underlying disease after it has been identified. Therapeutic goals should include improvement of hypoalbuminemia, edema, and lymphopenia.

  • The existing primary literature for therapy of PLE syndromes consists mainly of case reports and expert opinions, subject to substantial reporting bias and unknown rates of spontaneous remission; the rarity of and the diversity among this set of diseases make future large randomized trials unlikely. Therapeutic choices, therefore, must involve clinical acumen, empiricism, and understanding of the pathophysiology of the underlying disease process, and must be tailored to each individual patient’s syndrome.

  • Dietary interventions including hypolipidic, high-protein regimens, supplemented by medium-chain triglycerides (MCTs), are extremely useful, particularly in protein loss due to increased lymphatic pressure.

  • Corticosteroids can be very useful in certain cases of PLE (though not without substantial long-term toxicity) when clinical serologic or histologic markers of inflammatory disease are present. Octreotide is a well tolerated drug that has been demonstrated to improve PLE in some patients, and is worth consideration.

  • Octreotide is a well tolerated drug that has been demonstrated to improve PLE in some patients, and is worth consideration.

  • Surgery finds its best role in treating gastrointestinal protein loss from neoplasia, inflammatory bowel disease, and hypertrophic gastritis. Most other PLEs are distributed too widely for surgical intervention.

  • Protein-losing gastropathy (PLG) behaves somewhat differently from the general group of PLE, marked by excellent responses to elimination of Helicobacter pylori, antisecretory therapy, and surgical resection.

  • Protein-losing enteropathy stemming from cardiovascular disease is best treated by medical or surgical cardiovascular interventions; however, some patients may respond to mucosa-directed therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Pochapin MB: Protein-losing disorders of the gastrointestinal tract. In Clinical Practice of Gastroenterology. Edited by Brandt LJ. Philadelphia: Churchill Livingstone; 1999:476–483. Reviews the pathology, pathophysiology and clinical features of PLE with discussion of the most common underlying disease entities.

    Google Scholar 

  2. Albright F, Forbes AP, Barterr FC, et al.: Studies on fate of intravenously administered plasma proteins in idiopathic hypoproteinemia and osteoporosis. In Symposia on Nutrition. Edited by Youmans YB. Cincinnati: Robert Gould Research Foundation, 1950:352.

    Google Scholar 

  3. Waldmann TA, Wochner RD, Strober W: The role of the gastrointestinal tract in plasma protein metabolism. Am J Med 1969, 46:275–284.

    Article  PubMed  CAS  Google Scholar 

  4. Hess J, Kruizinga K, Bijleveld CMA, et al.: Protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg 1984, 88:606–609.

    PubMed  CAS  Google Scholar 

  5. Mertens L, Hagler DJ, Sauer U, et al.: Protein-losing enteropathy after the Fontan operation: an international multicenter study. J Thorac Cardiovasc Surg 1998, 115:1063–1073. Large review of 114 patients with PLE occurring after the Fontan procedure for congenital heart disease with interesting perspectives on the pathophysiology of PLE and the success of various treatment approaches tried in this specialized subset of PLE.

    Article  PubMed  CAS  Google Scholar 

  6. Lemes V, Murphy AM, Osterman FA, et al.: Fenestration of extracardiac Fontan and reversal of protein-losing enteropathy: case report. Pediatr Cardiol 1998, 19:355–357.

    Article  PubMed  CAS  Google Scholar 

  7. Warnes CA, Feldt RH, Hagler DJ: Protein-losing enteropathy after the Fontan operation: successful treatment by percutaneous fenestration of the atrial septum. Mayo Clin Proceed 1996, 71:378–379.

    Article  CAS  Google Scholar 

  8. Rychik J, Rome JJ, Jacobs ML: Late surgical fenestration for complications after the Fontan operation. Circulation 1997, 96:33–36.

    PubMed  CAS  Google Scholar 

  9. Sierra C, Calleja F, Picazo B, et al.: Protein-losing enteropathy secondary to Fontan procedure resolved after cardiac transplantation. J Pediatr Gastroenterol Nutr 1997, 24:229–230.

    Article  PubMed  CAS  Google Scholar 

  10. Therrien J, Webb GD, Gatzoulis MA: Reversal of protein losing enteropathy with prednisone in adults with modified Fontan operations: long term palliation or bridge to cardiac transplantation? Heart 1999, 82:241–243.

    PubMed  CAS  Google Scholar 

  11. Rychik J, Piccoli DA, Barber G: Usefulness of corticosteroid therapy for protein losing enteropathy after the Fontan procedure. Am J Cardiol 1991, 68:819–821.

    Article  PubMed  CAS  Google Scholar 

  12. Rothman A, Snyder J: Protein-losing enteropathy following the Fontan operation: resolution with prednisone therapy. Am Heart J 1991, 121:618–619.

    Article  PubMed  CAS  Google Scholar 

  13. Zellers TM, Brown K: Protein-losing enteropathy after the modified Fontan operation: oral prednisone treatment with biopsy and laboratory proved improvement. Pediatr Cardiol 1996, 17:115–117.

    Article  PubMed  CAS  Google Scholar 

  14. Bendayan I, Casaldaliga J, Castello F, Miro L: Heparin therapy and reversal of protein losing enteropathy in a case with congential heart disease. Pediatr Cardiol 2000, 21:267–268.

    Article  PubMed  CAS  Google Scholar 

  15. Kelly AM, Feldt RH, Driscoll DJ, et al.: Use of heparin in the treatment of protein-losing enteropathy after Fontan operation for complex congenital heart disease. Mayo Clin Proc 1998, 73:777–779.

    Article  PubMed  CAS  Google Scholar 

  16. Bernier JJ, Florent C, Desmazures C, et al.: Diagnosis of protein-losing enteropathy by gastrointestinal clearance of alpha1-antitrypsin. Lancet 1978, 2:763–764.

    Article  PubMed  CAS  Google Scholar 

  17. Strygler B, Nicor MJ, Santangelo WC, et al.: Alpha1-antitrypsin excretion in stool in normal subjects and in patients with gastrointestinal disorders. Gastroenterology 1990, 99:1380–1387.

    PubMed  CAS  Google Scholar 

  18. Florent C, L’Hirondel C, Desmazures C, et al.: Intestinal clearance of alpha 1-antitrypsin: a sensitive method for the detection of protein-losing enteropathy. Gastroenterology 1981, 81:777–780.

    PubMed  CAS  Google Scholar 

  19. Oommen R, Kurien G, Balakrishnan N, Narasimhan S: Tc-99m-albumin scintigraphy in the localization of protein loss in the gut. Clin Nucl Med 1992, 17:787–790.

    Article  PubMed  CAS  Google Scholar 

  20. Bhatnagar A, Lahoti D, Singh AK, et al.: Scintigraphic diagnosis of protein-losing enteropathy, using Tc-99m dextran. Clin Nucl Med 1993, 20:1070–1073.

    Article  Google Scholar 

  21. Bhatnagar A, Kashyap R, Chauhan UPS, et al.: Diagnosing protein-losing enteropathy: a new approach using Tc-99 human immunoglobulin. Clin Nucl Med 1995, 20:969–972.

    Article  PubMed  CAS  Google Scholar 

  22. Carpani de Kaski M, Peters AM, Bradley D, et al.: Detection and quantification of protein-losing enteropathy with indium-111 transferrin. Eur J Nucl Med 1996, 23:530–533.

    Article  Google Scholar 

  23. Bloom B, Chaikoff IL, Reinhardt WO: Intestinal lymph as pathway for transport of absorbed fatty acids of different chain lengths. Am J Physiol 1951, 166:451.

    PubMed  CAS  Google Scholar 

  24. Tift WL, Lloyd JK: Intestinal lymphangiectasia. Long-term results with MCT diet. Arch Dis Child 1975, 50:269–276.

    PubMed  CAS  Google Scholar 

  25. Simmonds WJ: The effect of fluid, electrolyte and food intake on thoracic duct lymph flow in unanaesthetized rats. Austr J Exp Biol Med Sci 1954, 32:285.

    CAS  Google Scholar 

  26. Holt PR: Dietary treatment of protein loss in intestinal lymphangiectasia. The effect of eliminating dietary long chain triglycerides on albumin metabolism in this condition. Pediatrics 1964, 34:629–635.

    PubMed  CAS  Google Scholar 

  27. Jeffries GH, Chapman A, Sleisenger MH: Low-fat diet intestinal lymphangiectasia. N Engl J Med 1964, 270:761–766.

    Article  PubMed  CAS  Google Scholar 

  28. Stoelinga GBA, VanMunster, EJJ, Slooff JF: Chylous effusions into intestine in patient with protein-losing gastroenteropathy. Pediatrics 1963, 31:1011–1081.

    PubMed  CAS  Google Scholar 

  29. Leyland FC, Fosbrooke AS, Lloyd JK, et al.: Use of medium chain triglyceride diets in children with malabsorption. Arch Dis Child 1969, 44:170–179.

    PubMed  CAS  Google Scholar 

  30. Alfano V, Tritto G, Alfonsi L, et al.: Stable reversal of pathologic signs of primitive intestinal lymphangiectasia with a hypolipidic, MCT-enriched diet. Nutrition 2000, 16:303–304.

    Article  PubMed  CAS  Google Scholar 

  31. Clinical Staff Conference: Idiopathic hypoalbuminemia —Clinical staff conference at National Institutes of Health. Ann Intern Med 1959, 51:53–576.

    Google Scholar 

  32. Fleischer TA, Strober W, Muchmore AV, et al.: Corticosteroid responsive intestinal lymphangiectasia secondary to an inflammatory process. N Engl J Med 1979, 300:605–606.

    Article  Google Scholar 

  33. Belaiche J, Vesin P, Carlet J, et al.: Entéropathie avec perte de protéines et syndrome inflammatoire: rémission speculaire après flash intraveineux de méthylprednisolone. Gastroenterol Clin Biol 1982, 6:438–442.

    PubMed  CAS  Google Scholar 

  34. Lebenthal E, Gaifman M, Nitzan M: Case report: protein-losing gastroenteropathy responding to corticosteroid treatment. Acta Paediatr Scand 1970, 59:217–220.

    PubMed  CAS  Google Scholar 

  35. Itoi K, Sasaki T, Sawai T, et al.: Protein-losing gastroenteropathy in association with immune deposits in gastrointestinal mucosal capillaries. Am J Gastroenterol 1989, 84:187–191.

    PubMed  CAS  Google Scholar 

  36. Bac DJ, Van Hagen PM, Postema PTE, et al.: Octreotide for protein losing enteropathy with intestinal lymphangiectasia. Lancet 1995, 345:1639.

    Article  PubMed  CAS  Google Scholar 

  37. Nakabayashi H, Sagara H, Usukura N, et al.: Effect of somatostatin on the flow rate and triglyceride levels of thoracic duct lymph in normal and vagotomized dogs. Diabetes 1981, 30:440–445.

    PubMed  CAS  Google Scholar 

  38. Reubi JC, Horisberger U, Waser B, et al.: Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology 1992, 103:1207–1214.

    PubMed  CAS  Google Scholar 

  39. Reubi JC, Waser B, Markusse HM, et al.: Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. Eur J Pharmacol 1994, 271:371–378.

    PubMed  CAS  Google Scholar 

  40. Ballinger AB, Farthing MJG: Octreotide in the treatment of intestinal lymphangiectasia. Eur J Gastroenterol Hepatol 1998, 10:699–702.

    PubMed  CAS  Google Scholar 

  41. Ratnoff OD: Increased vascular permeability induced by plasmin. J Exp Med 1965, 122:905–921.

    Article  CAS  PubMed  Google Scholar 

  42. Kondo M, Bamba T, Hosokawa K, et al.: Tissue plasminogen activator in the pathogenesis of protein-losing gastroenteropathy. Gastroenterology 1976, 70:1045–1047.

    PubMed  CAS  Google Scholar 

  43. Mine K, Matsubayashi S, Nakai Y, Nakagawa T: Intestinal lymphangiectasia markedly improved with antiplasmin therapy. Gastroenterology 1989, 96:1596–1599.

    PubMed  CAS  Google Scholar 

  44. Heresbach D, Raoul JL, Bretagne JF, Gosselin M: Intestinal lymphangiectasia: lack of efficacy of antiplasmin therapy? Gastroenterology 1991, 100:1152–1153.

    PubMed  CAS  Google Scholar 

  45. Cohen SA, Diuguid DL, Whitlock RT, Holt PR: Intestinal lymphangiectasia and antiplasmin therapy [letter]. Gastroenterology 1992, 102:2193.

    PubMed  CAS  Google Scholar 

  46. Persic M, Browse NL, Prpic I: Intestinal lymphangiectasia and protein losing enteropathy responding to small bowel resection [letter]. Arch Dis Childh 1998, 78:194.

    PubMed  CAS  Google Scholar 

  47. Mistilis SP, Skyring AP: Intestinal lymphangiectasia. Therapeutic effect of lymph venous anastomosis. Am J Med 1966, 40:634–641.

    Article  Google Scholar 

  48. Ivey K, DenBesten L, Kent TH, Clifton JA: Lymphangiectasia of the colon with protein loss and malabsorption. Gastroenterology 1969, 57:709–714.

    PubMed  CAS  Google Scholar 

  49. Waldmann TA, Steinfeld JL, Dutcher TF, et al.: The role of the gastrointestinal system in "idiopathic hypoproteinemia." Gastroenterology 1968, 54(suppl):795–796.

    PubMed  Google Scholar 

  50. Ménétrier P: Des polyadenomes gastriques et de leurs rapports avec le cancer de l’estomac. Arch Physiol Norm Pathol 1888, 4:32–35.

    Google Scholar 

  51. Citrin Y, Sterling K, Halstead JA: The mechanism of hypoproteinemia associated with giant hypertrophy of the gastric mucosa. N Engl J Med 1957, 257:906–912.

    Article  PubMed  CAS  Google Scholar 

  52. Crampton JR, Hunter JO, Neale G, et al.: Chronic lymphocytic gastritis and protein losing gastropathy. Gut 1989, 30(suppl):71–74.

    PubMed  Google Scholar 

  53. Schindler R: On hypertrophic glandular gastritis, hypertrophic gastropathy and parietal cell mass. Gastroenterology 1963, 45:77–83.

    PubMed  CAS  Google Scholar 

  54. Scharschmidt BF: The natural history of hypertrophic gastropathy. Am J Med 1977, 63:644–652.

    Article  PubMed  CAS  Google Scholar 

  55. Herskovic T, Spiro HM, Gryboski JD: Acute transient gastrointestinal protein loss. Pediatrics 1968, 41:818–821.

    PubMed  CAS  Google Scholar 

  56. Walker F: Spontaneous remission in hypertrophic gastropathy. South Med J 1981, 74:1273–1276.

    PubMed  Google Scholar 

  57. Groisman GM, George J, Berman D, Harpaz N: Resolution of protein-losing hypertrophic lymphocytic gastritis with therapeutic eradication of Helicobacter pylori. Am J Gastroenterol 1994, 89:1548–1551.

    PubMed  CAS  Google Scholar 

  58. Bayerdorffer E, Ritter MM, Hatz R, et al.: Menetrier’s disease and Helicobacter pylori [letter]. N Engl J Med 1993, 329:60.

    Article  PubMed  CAS  Google Scholar 

  59. Salmeron M, Desplaces N, Lavergne A, et al.: Campylobacter pylori, hypertrophic erosive gastritis and hypoalbuminemia healed by cephalexin therapy. Gastroenterol Clin Biol 1989, 13:109–110.

    PubMed  CAS  Google Scholar 

  60. Madsen LG, Taskiran M, Madsen JL, Bytzer P: Ménétrier’s disease and Helicobacter pylori: normalization of gastrointestinal protein loss after eradication therapy. Digest Dis Sci 1999, 44:2307–2312.

    Article  PubMed  CAS  Google Scholar 

  61. Crampton JR, Hunter JO, Neale G, Wight DGD: Chronic lymphocytic gastritis and protein-losing gastropathy. Gut 1989, 30:71–74.

    PubMed  Google Scholar 

  62. Meuwissen SGM, Ridwan BU, Hasper HJ, Innemee G: Hypertrophic protein-losing gastropathy. A retrospective analysis of 40 cases in the Netherlands. Scand J Gastroenterology Suppl 1992, 194:1–7. Like the article by Searcy and Malagelada [77], a large collection of patients with an uncommon disease, providing a useful broad overview of clinical presentations, prognosis, and therapeutic approaches taken.

    CAS  Google Scholar 

  63. Kang JY, Tang KF, Goh A, et al.: Remission of Menetrier’s disease associated with ranitidine administration. Austr N Z J Med 1990, 20:716–717.

    CAS  Google Scholar 

  64. Krol TC, Isenberg, JI Remission in a patient with Menetrier’s disease: spontaneous or induced by treatment? J Clin Gastroenterol 1985, 7:161–168.

    Article  PubMed  CAS  Google Scholar 

  65. Murata I, Yoshikawa I, Kuroda T, et al.: Varioliform gastritis and duodenitis associated with proteinlosing gastroenteropathy, treated with omeprazole. J Gastroenterol 1996, 31:109–113.

    Article  PubMed  CAS  Google Scholar 

  66. Bradburn DM, Redwood NF, Venables CW, Gunn A: Medical therapy of Ménétrier’s disease with omeprazole. Digestion 1992, 52:204–208.

    PubMed  CAS  Google Scholar 

  67. Ladas SD, Tassios PS, Malamou HC, et al.: Omeprazole induces a long-term clinical remission of proteinlosing gastropathy of Menetrier’s disease. Eur J Gastroenterol Hepatol 1997, 9:811–813.

    PubMed  CAS  Google Scholar 

  68. Krag E, Frederiksen HJ, Olsen N, Henriksen JH: Cimetidine treatment of protein-losing gastropathy (Ménétrier’s disease). A clinical and pathophysiological study. Scand J Gastroenterol 1978, 13:636–639.

    PubMed  CAS  Google Scholar 

  69. Kenny DG, Miller LJ, Malagelada JR, et al.: Giant hypertrophic gastropathy (Menetrier’s disease): Pharmacologic effects on protein leakage and mucosal ultrastructure. Gastroenterology 1982, 83:581–589.

    Google Scholar 

  70. Smith RL, Powell DW: Prolonged treatment of Menetrier’s disease with an anticholinergic drug. Gastroenterology 1978, 74:903–906.

    PubMed  CAS  Google Scholar 

  71. Davis GE, O’Rourke MC, Metz JR, et al.: Hypertrophic gastropathy symptoms responsive to prednisone. J Clin Gastroenterol 1991, 13:436–441.

    Article  PubMed  CAS  Google Scholar 

  72. Winney RJ, Gilmour HM, Matthews JD: Prednisolone in giant hypertrophic gastritis. (Menetrier’s disease) Am J Digest Dis 1976, 21:337–339.

    Article  PubMed  CAS  Google Scholar 

  73. Yeaton P, Frierson HF Jr: Octreotide reduces enteral protein losses in Ménétrier’s disease. Am J Gastroenterol 1993, 88:95–98.

    PubMed  CAS  Google Scholar 

  74. Kondo M, Ikezaki M, Kato H, Masuda M: Anti-fibrinolytic therapy of giant hypertrophic gastritis (Menetrier’s disease). Scand J Gastroenterol 1978, 13:851–856.

    Article  PubMed  CAS  Google Scholar 

  75. Balfour DC Jr, Hightower NC Jr, Gambill EE, et al.: Giant hypertrophy of the gastric rugae (Menetrier’s disease) associated with severe hypoproteinemia, relieved only by total gastrectomy: report of a case. Gastroenterology 1950, 16:773.

    PubMed  Google Scholar 

  76. Scharschmidt BF: The natural history of hypertrophic gastropathy (Menetrier’s disease). Report of a case with 16 year followup and review of 120 cases from the literature. Am J Med 1977, 63:644–652.

    Article  PubMed  CAS  Google Scholar 

  77. Searcy RM, Malagelada JR: Ménétrier’s disease and idiopathic hypertrophic gastropathy. Ann Intern Med 1984, 100:565–570.

    PubMed  CAS  Google Scholar 

  78. Scott HW, Shull HJ, Law DH, et al.: Surgical management of Ménétrier’s disease with protein-losing gastropathy. Ann Surg 1975, 181:765–777.

    Article  PubMed  Google Scholar 

  79. Sundt TM 3rd, Compton CC, Malt RA: Menetrier’s disease, a trivalent gastropathy. Ann Surg 1988, 208:694–701.

    Article  PubMed  Google Scholar 

  80. Gold BM, Meyers MA: Progression of Ménétrier’s disease with postoperative gastrojejunal intussusception. Gastroenterology 1977, 73:583–586.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Landzberg, B.R., Pochapin, M.B. Protein-losing enteropathy and gastropathy. Curr Treat Options Gastro 4, 39–49 (2001). https://doi.org/10.1007/s11938-001-0045-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-001-0045-z

Keywords

Navigation